Home page > About us > Press Releases
extra small siz normal size extra large size
print
email

Edit email address
Invalid email
Email Sent
Authorize the processing of personal data

Press Releases

October 2021
 
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the...
15/10/2021
 
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in...
15/10/2021
 
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for...
14/10/2021
 
September 2021
 
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Brazil for the...
13/09/2021
 
June 2021
 
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical...
02/06/2021
 
May 2021
 
Chiesi USA, Inc. Earns 2021 Life Sciences Award by Triangle Business Journal for second consecutive...
24/05/2021
 
Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of...
01/05/2021
 
April 2021
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for...
28/04/2021
 
February 2021
 
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying...
26/02/2021
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from...
23/02/2021
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of...
10/02/2021
 
December 2020
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III...
30/12/2020
 
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for...
23/12/2020
 
November 2020
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for...
27/11/2020
 
October 2020
 
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program...
02/10/2020
 
September 2020
 
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for...
17/09/2020
 
August 2020
 
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT...
25/08/2020
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration...
11/08/2020
 
July 2020
 
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
10/07/2020
 
June 2020
 
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
30/06/2020
 
May 2020
 
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License...
28/05/2020
 
January 2020
 
Chiesi acquires ApoPharma
13/01/2020